TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024

Rhea-AI Summary

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON) will report its Q4 and year-end 2023 financial results on March 5, 2024. The company focuses on developing novel cancer therapeutics and partnering with life science firms.

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its fourth quarter and year-end 2023 financial and operating results after the close of U.S. financial markets on Tuesday, March 5, 2024. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.

Date:	March 5, 2024
Time:	4:30 pm Eastern Time (1:30 pm Pacific Time)
Conference Call:	In order to participate in the live conference call, you must register in advance here: registration link. After registering, you will receive an email with dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.
Webcast:	https://traconpharma.com/events-presentations/

A replay of the webcast will be available for 60 days on the website.

About TRACON

TRACON is a clinical-stage biopharmaceutical company utilizing a cost-efficient, CRO-independent, product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1 development; and TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer. TRACON is actively seeking additional corporate partnerships through a profit-share or revenue-share partnership, or through franchising TRACON’s product development platform. TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States or who wish to become CRO-independent. To learn more about TRACON and its product pipeline, visit TRACON’s website at www.traconpharma.com.

Company Contact:	Investor Contact:
Charles Theuer	Brian Ritchie
Chief Executive Officer	LifeSci Advisors LLC
(858) 550-0780	(212) 915-2578
ctheuer@traconpharma.com

When will TRACON Pharmaceuticals report its Q4 and year-end 2023 financial results?

TRACON Pharmaceuticals will report its Q4 and year-end 2023 financial results on March 5, 2024.

What is the ticker symbol for TRACON Pharmaceuticals?

The ticker symbol for TRACON Pharmaceuticals is TCON.

What does TRACON Pharmaceuticals focus on?

TRACON Pharmaceuticals focuses on developing novel cancer therapeutics and partnering with life science companies.

How can I participate in the live conference call regarding TRACON Pharmaceuticals' financial results?

To participate in the live conference call, you must register in advance using the provided registration link.

Where can I find the webcast for TRACON Pharmaceuticals' conference call?

The webcast for TRACON Pharmaceuticals' conference call can be accessed at https://traconpharma.com/events-presentations/.